A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs GC 1102 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Green Cross
  • Most Recent Events

    • 14 Jan 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
    • 22 Aug 2012 Actual initiation date (Aug 2012) added as reported by ClinicalTrials.gov.
    • 22 Aug 2012 Planned End Date changed from 1 Jul 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top